KRMD stock holds focus as KORU Medical scales revenue

KORU Medical Systems Inc. (ISIN US5006311063) remains a numbers-driven story for KRMD stock, with the latest available report pointing to revenue, margin, and cash balance trends that shape the valuation debate. The company’s shares are tied to a business that serves infusion therapy users, and the most recent disclosed figures remain the main reference point for investors.

Revenue and margin set the frame

The latest company report showed revenue of 23.6 million dollars for the quarter, up from 18.7 million dollars a year earlier, a year-over-year increase of 26.2%. Gross margin reached 52.4% in that period, compared with 48.9% in the prior-year quarter, while adjusted EBITDA improved to a loss of 0.6 million dollars from a loss of 1.4 million dollars.

That mix matters because it shows the business adding scale while narrowing operating losses. Revenue growth of 26.2% is the clearest positive comparison in the set, and the margin move gives the expansion a clearer quality signal than revenue alone.

Cash still matters most

Cash and equivalents stood at 20.8 million dollars at the end of the latest reported quarter, while total debt remained at 0 dollars. For a smaller medtech name, that combination gives the company room to keep funding product work and commercial expansion without immediate balance-sheet pressure.

The same report also showed research and development expense of 1.7 million dollars and selling, general and administrative expense of 7.9 million dollars for the quarter. Those figures help explain why the company is still investing ahead of full profitability.

Infusion products carry the story

One of the most visible commercial drivers is the company’s infusion platform, including products used for subcutaneous therapy delivery. The latest reported revenue trajectory suggests that demand for the core system and related consumables remains central to the investment case.

In practical terms, investors are watching whether repeat product use can keep lifting revenue while operating costs rise more slowly. The reported gross margin improvement to 52.4% is the key sign that scale is beginning to help.

KRMD stock and the market view

KRMD stock trades on Nasdaq under the symbol KRMD, and the market continues to price it as a small-cap medical technology name with execution risk and growth potential in equal measure. The stock’s reading matters less as a headline move than as a reflection of how the market weighs 23.6 million dollars in quarterly revenue against a 0.6 million dollar adjusted EBITDA loss.

For now, the most useful comparison remains the year-over-year change: revenue up 26.2%, gross margin up to 52.4%, and adjusted EBITDA loss narrowed to 0.6 million dollars. Those three figures define the current setup better than any broader narrative.